Evidence map›Paper›PMID 42057054›Full record

ReviewCardiovascular diabetology2026

Cardiovascular-kidney-metabolic syndrome: a comprehensive review of pathophysiology, epidemiology, diagnosis, and management.

Stanislovas S Jankauskas, Klara Komici, Fahimeh Varzideh, Luigi Simone Aversa, Urna Kansakar, Maria Luisa D'Onghia, Shivangi Pande, Pasquale Mone, Gaetano Santulli

Abstract readReview
In one paragraph

Review in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Features of Lipid Disorders in Cardiovascular-Kidney-Metabolic Syndrome.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Stanislovas S Jankauskas *Department of Molecular, Cellular and Biomedical Sciences, School of Medicine, City University of New York, Manhattan, NY, USA.
Klara Komici *Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.
Fahimeh VarzidehDepartment of Molecular, Cellular and Biomedical Sciences, School of Medicine, City University of New York, Manhattan, NY, USA.
Luigi Simone AversaDepartment of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.
Urna KansakarDepartment of Molecular, Cellular and Biomedical Sciences, School of Medicine, City University of New York, Manhattan, NY, USA.
Maria Luisa D'OnghiaUnit of Plastic and Reconstructive Surgery, Department of Precision and Regenerative Medicine and Ionic Area, University "Aldo Moro", Bari, Italy.
Shivangi PandeDepartment of Molecular, Cellular and Biomedical Sciences, School of Medicine, City University of New York, Manhattan, NY, USA.
Pasquale MoneDepartment of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.
Gaetano SantulliDepartment of Molecular, Cellular and Biomedical Sciences, School of Medicine, City University of New York, Manhattan, NY, USA. gsantulli001@gmail.com.

Funding

American Heart Association AHA26POST1563063NHLBI NIH HHS R01-HL146691NIDDK NIH HHS R01-DK123259
6 · The paper itself

Abstract

Cardiovascular-kidney-metabolic (CKM) syndrome is a multisystem condition integrating metabolic dysfunction, chronic kidney disease (CKD), and cardiovascular disease into a unified framework. CKM syndrome encompasses progressive metabolic derangements, renal injury, and cardiovascular remodeling, which interact to amplify morbidity and mortality. Lifestyle interventions (including structured weight loss, dietary modification, physical activity, and sleep optimization) form a cornerstone of prevention and management. Pharmacologic strategies targeting the renin-angiotensin-aldosterone system, sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and lipid-lowering therapies provide additional multisystem benefits. In this comprehensive review, we systematically examine the most updated evidence on CKM syndrome, in terms of pathophysiology, epidemiology, clinical manifestations, diagnostic evaluation, and therapeutic strategies. We also highlight future research directions and precision medicine approaches.

Indexed as

Cardio-Renal SyndromeCardiovascular DiseasesKidneyMetabolic SyndromeRisk Reduction BehaviorAnimalsHumansPredictive Value of TestsPrognosisRisk AssessmentRisk FactorsTreatment OutcomeCardiologyCardiovascular diseaseCKMKidneyMetabolism

Identifiers

PMID42057054
PMCPMC13274062

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.